Based in Basel, BioMedPartners is a leading, independent European venture capital firm that acts frequently as lead-or co-lead investor providing private equity to early- to mid-stage life sciences companies. Since 2002, BioMedPartners has invested in several highly innovative companies of which 22 have already either successfully been acquired by leading biopharma companies or have completed an IPO.

With more than CHF 350 million in capital under management and a strong team of experienced industry experts as well as an extensive scientific network, BioMedPartners has established itself as one of the leading early-stage human healthcare investors in Europe. In February 2017 the company announced the first closing of BioMedInvest III, their third equity venture capital fund, with the final closing in February 2018 at CHF 100 million.

BB Pureos Bioventures is a newly formed venture capital fund, advised by Bellevue Asset Management, with offices in Zurich, London and New York. Active since 1993, Bellevue manages more than six billion dollars in the healthcare sector. Pureos exclusively invests in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. With its experienced and dedicated team of venture capitalists and biotech entrepreneurs, Pureos strives to impact patients’ lives by advancing innovative treatments for severe diseases.

Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export…).

InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen and Servier. InnoBio 2, with a first closing at €135 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds. For more information, please visit: and – Follow us on Twitter: @Bpifrance @BpifrancePresse

Schroder Adveq, founded in 1997 is a leading asset manager investing globally in private equity, having USD 10 billion of assets under management. Schroder Adveq’s client base comprises institutional investors such as pension funds, insurance companies, endowments, family offices, and other financial institutions located in Europe, North America, and the Asia-Pacific region. Schroder Adveq has offices in Zurich, Frankfurt, London, Jersey, New York, Beijing, and Hong Kong.

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 892.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 530 startups since 2005. Driven by its expertise, entrepreneurial spirit and passion, the HTGF team helps guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry and life sciences. To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. For more information:


You’re more than welcome to contact us. Just fill out the form bellow. And we’ll get back tou you as soon as possible.